Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HEXA | P06865 | 8/20 | 1.00 |
| ▸ | HEXB | P07686 | 8/20 | 1.00 |
| ▸ | DHFR | P00374 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | HTR1A | P08908 | 1/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | HTR2A | P28223 | 1/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.71 |
| ▸ | HTR2B | P41595 | 1/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3502224 | 0.86 | DHFR (0.78) | HEXAHEXBDHFRMEN1SLC22A1 | |
| SCHEMBL5835121 | 0.86 | HEXA (0.78) | HEXAHEXBDHFRMEN1SLC22A1 | |
| SCHEMBL8261006 | 0.84 | HEXA (1.00) | HEXAHEXBDHFRMEN1SLC22A1 | |
| SCHEMBL8261612 | 0.84 | HEXA (0.73) | HEXAHEXBDHFRMEN1SLC22A1 | |
| SCHEMBL12368269 | 0.84 | HEXA (0.73) | HEXAHEXBDHFRMEN1SLC22A1 | |
| SCHEMBL12368256 | 0.83 | HEXA (0.73) | HEXAHEXBDHFRMEN1SLC22A1 | |
| Pyrimethamine SCHEMBL25129 | 0.83 | HEXA (1.00) | HEXAHEXBDHFRMEN1SLC22A1 | |
| Pyrimethamine SCHEMBL29381161 | 0.83 | HEXA (1.00) | HEXAHEXBDHFRMEN1SLC22A1 | |
| Pyrimethamine SCHEMBL15516970 | 0.83 | HEXA (1.00) | HEXAHEXBDHFRMEN1SLC22A1 | |
| SCHEMBL12368253 | 0.82 | HEXA (1.00) | HEXAHEXBDHFRMEN1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220289686-A1 | COMPOSITIONS OF NRF2 INHIBITING AGENTS AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY | 2022-09-15 | — | — | US | disclosed |
| US-20160369237-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECH INC (US) | 2016-12-22 | — | — | US | disclosed |
| US-20150272951-A1 | COMPOUNDS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | HOSPITAL FOR SICK CHILDREN (CA) | 2015-10-01 | — | — | US | disclosed |
| US-20150272951-A1 | COMPOUNDS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | HOSPITAL FOR SICK CHILDREN (CA) | 2015-10-01 | — | — | US | disclosed |
| US-9000003-B2 | Anti-folate antimalarials with dual-binding modes and their preparation | NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY (TH) | 2015-04-07 | — | — | US | disclosed |
| US-9000003-B2 | Anti-folate antimalarials with dual-binding modes and their preparation | NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY (TH) | 2015-04-07 | — | — | US | disclosed |
| WO-2012121682-A2 | ANTI-FOLATE ANTIMALARIALS WITH DUAL-BINDING MODES AND THEIR PREPARATION | NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY (TH) | 2012-09-13 | — | — | WO | disclosed |
| US-20110195985-A1 | COMPOUNDS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | THE HOSPITAL FOR SICK CHILDREN (CA) | 2011-08-11 | — | — | US | disclosed |
| US-20110195985-A1 | COMPOUNDS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | THE HOSPITAL FOR SICK CHILDREN (CA) | 2011-08-11 | — | — | US | disclosed |
| EP-1917017-B1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS WITH PYRIMETHAMINE AND ANALOGUES | ALSGEN INC (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20080226601-A1 | Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods | UNIVERSITY OF ROCHESTER (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1903873-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | THE UNIVERSITY OF ROCHESTER (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20080070303-A1 | Using myocardial and/or muscle progenitor cells as modeling tool in tissue engineering; regenerative medicine and organ replacement | ADVANCED CELL TECHNOLOGY | 2008-03-20 | — | — | US | disclosed |
| WO-2007062198-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECHNOLOGY, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006135602-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | UNIVERSITY OF ROCHESTER (US) | 2006-12-21 | — | — | WO | disclosed |
| EP-0751170-B1 | Silicone derivatives, their production and use | CHIBA FLOUR MILLING (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-5859243-A | AMINOSILICONES HAVING PYRIMIDINYL GROUPS BOUND TO THE AMINO GROUPS; USED TO GEL SILICONE OIL OR TO INCREASE THE VISCOSITY STABLY AND HOMOGENEOUSLY; BASES FOR COSMETICS, DRUGS, INDUSTRIAL MATERIAL; FEEL; TEXTURE | CHIBA FLOUR MILLING CO., LTD. (JP) | 1999-01-12 | — | — | US | disclosed |
| US-5712391-A | POLYSILOXANES MODIFIED WITH TRIAZINE GROUPS AND DIAMINE COMPOUNDS FOR COSMETICS | CHIBA FLOUR MILLING CO., LTD. (JP) | 1998-01-27 | — | — | US | disclosed |
| EP-0751170-A2 | Silicone derivatives, their production and use | Chiba Flour Milling Co., Ltd. (JP) | 1997-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150272951-A1 | COMPOUNDS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | GAA, GBA1, MAN2B1 | HEXA 48/4885HEXB 59/4885DHFR 960/4885 |
| US-20220289686-A1 | COMPOSITIONS OF NRF2 INHIBITING AGENTS AND METHODS OF USE THEREOF | KEAP1, GSTK1, NFE2L2 | HEXA 3816/4885HEXB 3849/4885DHFR 1701/4885 |
| US-20110195985-A1 | COMPOUNDS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | GAA, GBA1, MAN2B1 | HEXA 48/4885HEXB 59/4885DHFR 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.